- Coca-Cola Amatil partners with Indonesian start-ups
- RMIT researchers develop innovative wound dressing that detects infection and improves healing
- Solpod signs OEM agreement with German solar mounting solutions maker in Australia
- Deakin University and Visy share insights on the future of Industrial 4.0 CX
The expiration of patents, industry
restructuring and other factors will put a squeeze on the pharmaceutical industry,
according to a new report.
The research firm notes that the
industry surveyed employs 15,275 at 147 businesses nationally, and revenues
will reach $9.9 billion for the year (up from $9.0 billion in 2008-2009). Annualised
revenue increases are put at 1.7 per cent.
It is also, despite being a net
importer, one of Australia’s leading high-tech exports.
Dragging on growth, explains the
report, are a number of key medicines coming off-patent in 2011-2015, as well
as increased safety concerns and global rationalisation.
The report follows tough predictions made by IBISWorld in January last year, estimating industry revenue would decline by 2.1 per cent for 2012-13.